Mesoblast Limited [NASDAQ: MESO] gained 1.37% on the last trading session, reaching $3.34 price per share at the time. The company report on March 21, 2023 that FDA Schedules Pre-License Inspection of Remestemcel-L Manufacturing.
Biologics License Application (BLA) Resubmission for Pediatric Acute Graft-Versus-Host Disease (SR-aGVHD) Currently Being Reviewed.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Mesoblast Limited represents 147.32 million in outstanding shares, while the company has a total market value of $477.65 million with the latest information. MESO stock price has been found in the range of $3.17 to $3.44.
If compared to the average trading volume of 146.59K shares, MESO reached a trading volume of 74493 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Mesoblast Limited [MESO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MESO shares is $10.62 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MESO stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
William Blair have made an estimate for Mesoblast Limited shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on March 09, 2023. The new note on the price target was released on December 06, 2022, representing the official price target for Mesoblast Limited stock. Previously, the target price had yet another raise to $7, while Piper Sandler analysts kept a Overweight rating on MESO stock.
The Average True Range (ATR) for Mesoblast Limited is set at 0.16, with the Price to Sales ratio for MESO stock in the period of the last 12 months amounting to 60.46. The Price to Book ratio for the last quarter was 0.99, with the Price to Cash per share for the same quarter was set at 0.47.
Trading performance analysis for MESO stock
Mesoblast Limited [MESO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.03. With this latest performance, MESO shares dropped by -10.93% in over the last four-week period, additionally plugging by 12.08% over the last 6 months – not to mention a drop of -20.85% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MESO stock in for the last two-week period is set at 54.18, with the RSI for the last a single of trading hit 58.69, and the three-weeks RSI is set at 52.30 for Mesoblast Limited [MESO]. The present Moving Average for the last 50 days of trading for this stock 3.37, while it was recorded at 3.32 for the last single week of trading, and 3.12 for the last 200 days.
Mesoblast Limited [MESO]: A deeper dive into fundamental analysis
Mesoblast Limited’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.40.
Mesoblast Limited [MESO]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MESO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Mesoblast Limited go to 48.80%.
An analysis of insider ownership at Mesoblast Limited [MESO]
Positions in Mesoblast Limited stocks held by institutional investors increased at the end of Thursday and at the time of the Thursday reporting period, where 22 institutional holders increased their position in Mesoblast Limited [NASDAQ:MESO] by around 664,794 shares. Additionally, 12 investors decreased positions by around 1,515,438 shares, while 14 investors held positions by with 655,180 shares. The mentioned changes placed institutional holdings at 2,835,412 shares, according to the latest SEC report filing. MESO stock had 13 new institutional investments in for a total of 625,749 shares, while 3 institutional investors sold positions of 60,382 shares during the same period.